

## Recombinant Mouse VEGFR3/FLT4 Protein (His Tag)

Catalog Number: PKSM040596

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Species</b>	Mouse
<b>Source</b>	HEK293 Cells-derived Mouse VEGFR3/FLT4 protein Met 1-Glu 775, with an C-terminal His
<b>Calculated MW</b>	86.4 kDa
<b>Observed MW</b>	95-105 kDa
<b>Accession</b>	P35917-1
<b>Bio-activity</b>	Immobilized mouse VEGFR3-His at 10 µg/mL (100 µl/well) can bind mouse Fc-VEGFD, The EC <sub>50</sub> of mouse Fc-VEGFD is 44 ng/mL.

### Properties

<b>Purity</b>	> 97 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



Measured by its binding ability in a functional ELISA.

Immobilized mouse VEGFR3-His (Cat: PKSM040596) at 10 µg/mL (100 µl/well) can bind mouse Fc-VEGFD, The EC<sub>50</sub> of mouse Fc-VEGFD is 44 ng/mL.

### Background

#### For Research Use Only

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Fik-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

## For Research Use Only

Toll-free: 1-888-852-8623  
Web: [www.elabscience.com](http://www.elabscience.com)

Tel: 1-832-243-6086  
Email: [techsupport@elabscience.com](mailto:techsupport@elabscience.com)

Fax: 1-832-243-6017